Chaperone-mediated autophagy is required for tumor growth

Maria Kon, Roberta Kiffin, Hiroshi Koga, Javier Chapochnick, Fernando Macian-Juan, Lyuba Varticovski, Ana Maria Cuervo

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

The cellular process of autophagy (literally "self-eating") is important for maintaining the homeostasis and bioenergetics of mammalian cells. Two of the best-studied mechanisms of autophagy are macroautophagy and chaperone-mediated autophagy (CMA). Changes in macroautophagy activity have been described in cancer cells and in solid tumors, and inhibition of macroautophagy promotes tumorigenesis. Because normal cells respond to inhibition of macroautophagy by up-regulation of the CMA pathway, we aimed to characterize the CMA status in different cancer cells and to determine the contribution of changes in CMA to tumorigenesis. Here, we show consistent up-regulation of CMA in different types of cancer cells regardless of the status of macroautophagy. We also demonstrate an increase in CMA components in human cancers of different types and origins. CMA is required for cancer cell proliferation in vitro because it contributes to the maintenance of the metabolic alterations characteristic of malignant cells. Using human lung cancer xenografts in mice, we confirmed the CMA dependence of cancer cells in vivo. Inhibition of CMA delays xenograft tumor growth, reduces the number of cancer metastases, and induces regression of existing human lung cancer xenografts in mice. The fact that similar manipulations of CMA also reduce tumor growth of two different melanoma cell lines suggests that targeting this autophagic pathway may have broad antitumorigenic potential.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume3
Issue number109
DOIs
StatePublished - Nov 16 2011

Fingerprint

Autophagy
Growth
Neoplasms
Heterografts
Lung Neoplasms
Carcinogenesis
Up-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chaperone-mediated autophagy is required for tumor growth. / Kon, Maria; Kiffin, Roberta; Koga, Hiroshi; Chapochnick, Javier; Macian-Juan, Fernando; Varticovski, Lyuba; Cuervo, Ana Maria.

In: Science Translational Medicine, Vol. 3, No. 109, 16.11.2011.

Research output: Contribution to journalArticle

Kon, Maria ; Kiffin, Roberta ; Koga, Hiroshi ; Chapochnick, Javier ; Macian-Juan, Fernando ; Varticovski, Lyuba ; Cuervo, Ana Maria. / Chaperone-mediated autophagy is required for tumor growth. In: Science Translational Medicine. 2011 ; Vol. 3, No. 109.
@article{70227cb9920c4940a0ab2e1560b6a29a,
title = "Chaperone-mediated autophagy is required for tumor growth",
abstract = "The cellular process of autophagy (literally {"}self-eating{"}) is important for maintaining the homeostasis and bioenergetics of mammalian cells. Two of the best-studied mechanisms of autophagy are macroautophagy and chaperone-mediated autophagy (CMA). Changes in macroautophagy activity have been described in cancer cells and in solid tumors, and inhibition of macroautophagy promotes tumorigenesis. Because normal cells respond to inhibition of macroautophagy by up-regulation of the CMA pathway, we aimed to characterize the CMA status in different cancer cells and to determine the contribution of changes in CMA to tumorigenesis. Here, we show consistent up-regulation of CMA in different types of cancer cells regardless of the status of macroautophagy. We also demonstrate an increase in CMA components in human cancers of different types and origins. CMA is required for cancer cell proliferation in vitro because it contributes to the maintenance of the metabolic alterations characteristic of malignant cells. Using human lung cancer xenografts in mice, we confirmed the CMA dependence of cancer cells in vivo. Inhibition of CMA delays xenograft tumor growth, reduces the number of cancer metastases, and induces regression of existing human lung cancer xenografts in mice. The fact that similar manipulations of CMA also reduce tumor growth of two different melanoma cell lines suggests that targeting this autophagic pathway may have broad antitumorigenic potential.",
author = "Maria Kon and Roberta Kiffin and Hiroshi Koga and Javier Chapochnick and Fernando Macian-Juan and Lyuba Varticovski and Cuervo, {Ana Maria}",
year = "2011",
month = "11",
day = "16",
doi = "10.1126/scitranslmed.3003182",
language = "English (US)",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "109",

}

TY - JOUR

T1 - Chaperone-mediated autophagy is required for tumor growth

AU - Kon, Maria

AU - Kiffin, Roberta

AU - Koga, Hiroshi

AU - Chapochnick, Javier

AU - Macian-Juan, Fernando

AU - Varticovski, Lyuba

AU - Cuervo, Ana Maria

PY - 2011/11/16

Y1 - 2011/11/16

N2 - The cellular process of autophagy (literally "self-eating") is important for maintaining the homeostasis and bioenergetics of mammalian cells. Two of the best-studied mechanisms of autophagy are macroautophagy and chaperone-mediated autophagy (CMA). Changes in macroautophagy activity have been described in cancer cells and in solid tumors, and inhibition of macroautophagy promotes tumorigenesis. Because normal cells respond to inhibition of macroautophagy by up-regulation of the CMA pathway, we aimed to characterize the CMA status in different cancer cells and to determine the contribution of changes in CMA to tumorigenesis. Here, we show consistent up-regulation of CMA in different types of cancer cells regardless of the status of macroautophagy. We also demonstrate an increase in CMA components in human cancers of different types and origins. CMA is required for cancer cell proliferation in vitro because it contributes to the maintenance of the metabolic alterations characteristic of malignant cells. Using human lung cancer xenografts in mice, we confirmed the CMA dependence of cancer cells in vivo. Inhibition of CMA delays xenograft tumor growth, reduces the number of cancer metastases, and induces regression of existing human lung cancer xenografts in mice. The fact that similar manipulations of CMA also reduce tumor growth of two different melanoma cell lines suggests that targeting this autophagic pathway may have broad antitumorigenic potential.

AB - The cellular process of autophagy (literally "self-eating") is important for maintaining the homeostasis and bioenergetics of mammalian cells. Two of the best-studied mechanisms of autophagy are macroautophagy and chaperone-mediated autophagy (CMA). Changes in macroautophagy activity have been described in cancer cells and in solid tumors, and inhibition of macroautophagy promotes tumorigenesis. Because normal cells respond to inhibition of macroautophagy by up-regulation of the CMA pathway, we aimed to characterize the CMA status in different cancer cells and to determine the contribution of changes in CMA to tumorigenesis. Here, we show consistent up-regulation of CMA in different types of cancer cells regardless of the status of macroautophagy. We also demonstrate an increase in CMA components in human cancers of different types and origins. CMA is required for cancer cell proliferation in vitro because it contributes to the maintenance of the metabolic alterations characteristic of malignant cells. Using human lung cancer xenografts in mice, we confirmed the CMA dependence of cancer cells in vivo. Inhibition of CMA delays xenograft tumor growth, reduces the number of cancer metastases, and induces regression of existing human lung cancer xenografts in mice. The fact that similar manipulations of CMA also reduce tumor growth of two different melanoma cell lines suggests that targeting this autophagic pathway may have broad antitumorigenic potential.

UR - http://www.scopus.com/inward/record.url?scp=81455128769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81455128769&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003182

DO - 10.1126/scitranslmed.3003182

M3 - Article

C2 - 22089453

AN - SCOPUS:81455128769

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 109

ER -